Literature DB >> 15785757

Natural regulatory T cells and self-tolerance.

Ronald H Schwartz1.   

Abstract

The adaptive immune system allows individual organisms to mount defensive reactions against unanticipated pathogens by developmentally creating a diverse repertoire of clonally distributed receptors capable of recognizing a multitude of antigens and then expanding as effector cell populations those that can recognize molecules from the pathogens. To function properly, the system must deal with the problem of randomly generated receptors that can recognize self components. Most solutions to this self-tolerance problem are cell intrinsic and involve the deletion or inactivation of autoreactive cells. However, an extrinsic form of dominant tolerance has been demonstrated that takes the form of CD4(+) regulatory T cells. This perspective discusses why such a mechanism might have evolved and the problems it presents for self-non-self discrimination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785757     DOI: 10.1038/ni1184

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  62 in total

1.  A clonal model for human CD8+ regulatory T cells: unrestricted contact-dependent killing of activated CD4+ T cells.

Authors:  Dan Hu; Xia Liu; Wanyong Zeng; Howard L Weiner; Jerome Ritz
Journal:  Eur J Immunol       Date:  2011-11-28       Impact factor: 5.532

Review 2.  Transplant tolerance: models, concepts and facts.

Authors:  Nicola J Monk; Roseanna E G Hargreaves; Elizabeth Simpson; Julian P Dyson; Stipo Jurcevic
Journal:  J Mol Med (Berl)       Date:  2006-02-25       Impact factor: 4.599

3.  NF-kappaB2 is required for the control of autoimmunity by regulating the development of medullary thymic epithelial cells.

Authors:  Baochun Zhang; Zhe Wang; Jane Ding; Pärt Peterson; William T Gunning; Han-Fei Ding
Journal:  J Biol Chem       Date:  2006-10-17       Impact factor: 5.157

Review 4.  Epithelia: lymphocyte interactions in the gut.

Authors:  Stephanie Dahan; Franziska Roth-Walter; Paul Arnaboldi; Shradha Agarwal; Lloyd Mayer
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

5.  T cell receptor Vbeta repertoire of T lymphocytes and T regulatory cells by flow cytometric analysis in healthy children.

Authors:  A McLean-Tooke; D Barge; G P Spickett; A R Gennery
Journal:  Clin Exp Immunol       Date:  2007-11-05       Impact factor: 4.330

6.  FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression.

Authors:  Bin Li; Arabinda Samanta; Xiaomin Song; Kathryn T Iacono; Kathryn Bembas; Ran Tao; Samik Basu; James L Riley; Wayne W Hancock; Yuan Shen; Sandra J Saouaf; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-07       Impact factor: 11.205

7.  Crystallization and initial crystal characterization of the C-terminal phosphoglycerate mutase homology domain of Sts-1.

Authors:  Holly Kleinman; Bradley Ford; James Keller; Nick Carpino; Nicolas Nassar
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-02-10

8.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

9.  Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors.

Authors:  Maria I Christodoulou; Efstathia K Kapsogeorgou; Niki M Moutsopoulos; Haralampos M Moutsopoulos
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

10.  Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.

Authors:  Baldev Vasir; Zekui Wu; Keith Crawford; Jacalyn Rosenblatt; Corrine Zarwan; Adam Bissonnette; Donald Kufe; David Avigan
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.